Straits Times Index
3,109.05 +34.79 (+1.13%) Nikkei
32,307.86 -550.45 (-1.68%) Hang Seng
16,335.24 -10.65 (-0.07%) FTSE 100
7,513.72 -1.66 (-0.02%) Bitcoin USD
43,396.45 -515.07 (-1.17%) CMC Crypto 200
898.85 +6.13 (+0.69%)
Precigen, Inc. (PGEN)
After hours:
- PR Newswire
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 3:00 PM ET.
- PR Newswire
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2023 financial results and progress of clinical programs.
- PR Newswire
Precigen to Participate in the Stifel 2023 Healthcare Conference
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a company overview at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 10:55 AM ET in New York.
